Lantheus Holdings, Inc.

Lantheus Holdings is a radiopharmaceutical company whose core business involves the development and commercialization of diagnostic imaging agents. A significant portion of its product pipeline and revenue is derived from agents that are tested on animals as part of the regulatory approval process required by the FDA and other global health authorities. This reliance on animal testing for product development and market authorization constitutes commercial exploitation of animals.

The company’s annual filings disclose that its operations are subject to extensive regulation, including preclinical testing requirements that involve animal studies to demonstrate safety and efficacy. While the provided evidence does not detail specific testing protocols or volumes, the business model of a radiopharmaceutical developer inherently depends on animal-based research to bring new products to market. There is no public commitment from Lantheus to adopt or fund the development of non-animal testing methodologies as a strategic alternative.